Long-term measles antibody profiles following different vaccine schedules in China, a longitudinal study

Qianli Wang; Wei Wang; Amy K. Winter; Zhifei Zhan; Marco Ajelli; Filippo Trentini; Lili Wang; Fangcai Li; Juan Yang; Xingyu Xiang; Qiaohong Liao; Jiaxin Zhou; Jinxin Guo; Xuemei Yan; Nuolan Liu; C. Jessica E. Metcalf; Bryan T. Grenfell; Hongjie Yu

doi:10.1038/s41467-023-37407-x

Long-term measles antibody profiles following different vaccine schedules in China, a longitudinal study

Qianli Wang, Wei Wang, Amy K. Winter, Zhifei Zhan, Marco Ajelli, Filippo Trentini, Lili Wang, Fangcai Li, Juan Yang, Xingyu Xiang, Qiaohong Liao, Jiaxin Zhou, Jinxin Guo, Xuemei Yan, Nuolan Liu, C. Jessica E. Metcalf, Bryan T. Grenfell, Hongjie Yu

Research output: Contribution to journal › Article › peer-review

9 Scopus citations

Abstract

Characterizing the long-term kinetics of maternally derived and vaccine-induced measles immunity is critical for informing measles immunization strategies moving forward. Based on two prospective cohorts of children in China, we estimate that maternally derived immunity against measles persists for 2.4 months. Following two-dose series of measles-containing vaccine (MCV) at 8 and 18 months of age, the immune protection against measles is not lifelong, and antibody concentrations are extrapolated to fall below the protective threshold of 200 mIU/ml at 14.3 years. A catch-up MCV dose in addition to the routine doses between 8 months and 5 years reduce the cumulative incidence of seroreversion by 79.3–88.7% by the age of 6 years. Our findings also support a good immune response after the first MCV vaccination at 8 months. These findings, coupled with the effectiveness of a catch-up dose in addition to the routine doses, could be instrumental to relevant stakeholders when planning routine immunization schedules and supplemental immunization activities.

Original language	English (US)
Article number	1746
Journal	Nature communications
Volume	14
Issue number	1
DOIs	https://doi.org/10.1038/s41467-023-37407-x
State	Published - Dec 2023

All Science Journal Classification (ASJC) codes

General Chemistry
General Biochemistry, Genetics and Molecular Biology
General Physics and Astronomy

Access to Document

10.1038/s41467-023-37407-x

Cite this

Wang, Q., Wang, W., Winter, A. K., Zhan, Z., Ajelli, M., Trentini, F., Wang, L., Li, F., Yang, J., Xiang, X., Liao, Q., Zhou, J., Guo, J., Yan, X., Liu, N., Metcalf, C. J. E., Grenfell, B. T., & Yu, H. (2023). Long-term measles antibody profiles following different vaccine schedules in China, a longitudinal study. Nature communications, 14(1), Article 1746. https://doi.org/10.1038/s41467-023-37407-x

@article{a3716f90cb944efe83b0241b4f997720,

title = "Long-term measles antibody profiles following different vaccine schedules in China, a longitudinal study",

abstract = "Characterizing the long-term kinetics of maternally derived and vaccine-induced measles immunity is critical for informing measles immunization strategies moving forward. Based on two prospective cohorts of children in China, we estimate that maternally derived immunity against measles persists for 2.4 months. Following two-dose series of measles-containing vaccine (MCV) at 8 and 18 months of age, the immune protection against measles is not lifelong, and antibody concentrations are extrapolated to fall below the protective threshold of 200 mIU/ml at 14.3 years. A catch-up MCV dose in addition to the routine doses between 8 months and 5 years reduce the cumulative incidence of seroreversion by 79.3–88.7% by the age of 6 years. Our findings also support a good immune response after the first MCV vaccination at 8 months. These findings, coupled with the effectiveness of a catch-up dose in addition to the routine doses, could be instrumental to relevant stakeholders when planning routine immunization schedules and supplemental immunization activities.",

author = "Qianli Wang and Wei Wang and Winter, {Amy K.} and Zhifei Zhan and Marco Ajelli and Filippo Trentini and Lili Wang and Fangcai Li and Juan Yang and Xingyu Xiang and Qiaohong Liao and Jiaxin Zhou and Jinxin Guo and Xuemei Yan and Nuolan Liu and Metcalf, {C. Jessica E.} and Grenfell, {Bryan T.} and Hongjie Yu",

note = "Publisher Copyright: {\textcopyright} 2023, The Author(s).",

year = "2023",

month = dec,

doi = "10.1038/s41467-023-37407-x",

language = "English (US)",

volume = "14",

journal = "Nature communications",

issn = "2041-1723",

publisher = "Nature Publishing Group",

number = "1",

}

Wang, Q, Wang, W, Winter, AK, Zhan, Z, Ajelli, M, Trentini, F, Wang, L, Li, F, Yang, J, Xiang, X, Liao, Q, Zhou, J, Guo, J, Yan, X, Liu, N, Metcalf, CJE , Grenfell, BT & Yu, H 2023, 'Long-term measles antibody profiles following different vaccine schedules in China, a longitudinal study', Nature communications, vol. 14, no. 1, 1746. https://doi.org/10.1038/s41467-023-37407-x

TY - JOUR

T1 - Long-term measles antibody profiles following different vaccine schedules in China, a longitudinal study

AU - Wang, Qianli

AU - Wang, Wei

AU - Winter, Amy K.

AU - Zhan, Zhifei

AU - Ajelli, Marco

AU - Trentini, Filippo

AU - Wang, Lili

AU - Li, Fangcai

AU - Yang, Juan

AU - Xiang, Xingyu

AU - Liao, Qiaohong

AU - Zhou, Jiaxin

AU - Guo, Jinxin

AU - Yan, Xuemei

AU - Liu, Nuolan

AU - Metcalf, C. Jessica E.

AU - Grenfell, Bryan T.

AU - Yu, Hongjie

PY - 2023/12

Y1 - 2023/12

N2 - Characterizing the long-term kinetics of maternally derived and vaccine-induced measles immunity is critical for informing measles immunization strategies moving forward. Based on two prospective cohorts of children in China, we estimate that maternally derived immunity against measles persists for 2.4 months. Following two-dose series of measles-containing vaccine (MCV) at 8 and 18 months of age, the immune protection against measles is not lifelong, and antibody concentrations are extrapolated to fall below the protective threshold of 200 mIU/ml at 14.3 years. A catch-up MCV dose in addition to the routine doses between 8 months and 5 years reduce the cumulative incidence of seroreversion by 79.3–88.7% by the age of 6 years. Our findings also support a good immune response after the first MCV vaccination at 8 months. These findings, coupled with the effectiveness of a catch-up dose in addition to the routine doses, could be instrumental to relevant stakeholders when planning routine immunization schedules and supplemental immunization activities.

AB - Characterizing the long-term kinetics of maternally derived and vaccine-induced measles immunity is critical for informing measles immunization strategies moving forward. Based on two prospective cohorts of children in China, we estimate that maternally derived immunity against measles persists for 2.4 months. Following two-dose series of measles-containing vaccine (MCV) at 8 and 18 months of age, the immune protection against measles is not lifelong, and antibody concentrations are extrapolated to fall below the protective threshold of 200 mIU/ml at 14.3 years. A catch-up MCV dose in addition to the routine doses between 8 months and 5 years reduce the cumulative incidence of seroreversion by 79.3–88.7% by the age of 6 years. Our findings also support a good immune response after the first MCV vaccination at 8 months. These findings, coupled with the effectiveness of a catch-up dose in addition to the routine doses, could be instrumental to relevant stakeholders when planning routine immunization schedules and supplemental immunization activities.

UR - http://www.scopus.com/inward/record.url?scp=85151225528&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85151225528&partnerID=8YFLogxK

U2 - 10.1038/s41467-023-37407-x

DO - 10.1038/s41467-023-37407-x

M3 - Article

C2 - 36990986

AN - SCOPUS:85151225528

SN - 2041-1723

VL - 14

JO - Nature communications

JF - Nature communications

IS - 1

M1 - 1746

ER -

Long-term measles antibody profiles following different vaccine schedules in China, a longitudinal study

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this